{"name":"ImmunAbs Inc.","slug":"immunabs-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPeHJXaDk1cXI0OFh5bU1aNmdhR05FeE1lV2ZCZHBQNWtSd3BqdFVpUGkyX3p2aFBFWl9SSEE4eFdjRjl1TlplMWRvVVhVSXM5Q2VtVk4wblhhY3NTSzZaUENyWDY5S2hMVUswOEVSb21QYUlPRDdQOG1oTkVGTUtpRmt5aG8tZGl2QjM3b0t4WjdiTTBENXpLT3VmdWlZeGxxTlZyWW9abGNkN0xsb0JncFIyZEVFaERnWDNHZzRUVld2Nm1zQ1lxSFduNVVRWU53M09paFo2bjR3dGJnX0dYbFphcmVYUy1PVktJVDJXelZ6TThDdHFLMnVLZTRwZ2JkbkVKel9tbU4?oc=5","date":"2025-06-02","type":"regulatory","source":"Business Wire","summary":"ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis - Business Wire","headline":"ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Grav","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFAyVnpmMEJ5Nlprc3MwRXVqTjFycDVpUGhhekZqOV9XT09rRkFOeEZlc2lYWFl0bG9tV0VTcXdvcTJucVhyOWt0alZ1dVdlSnU2NmFKN1NUWQ?oc=5","date":"2023-06-07","type":"pipeline","source":"바이오스펙테이터","summary":"ImmunAbs, developing a novel C5 antibody for complement-associated autoimmunity - 바이오스펙테이터","headline":"ImmunAbs, developing a novel C5 antibody for complement-associated autoimmunity - 바이오스펙테이터","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}